AI Article Synopsis

Article Abstract

We investigated the possible association of uncoupling protein 3 gene () single nucleotide polymorphisms (SNPs) with nonalcoholic steatohepatitis (NASH) and metabolic syndrome (MetS) in nonalcoholic fatty liver disease (NAFLD) Brazilian patients. SNPs rs1726745, rs3781907, and rs11235972 were genotyped in 158 biopsy-proven NAFLD Brazilian patients. Statistics was performed with JMP, R, and SHEsis softwares. The TT genotype of rs1726745 was associated with less occurrence of MetS ( = 0.006) and with lower body mass index (BMI) in the entire NAFLD sample ( = 0.01) and in the NASH group ( = 0.02). The rs1726745-T was associated with lower values of AST ( = 0.001), ALT ( = 0.0002), triglycerides ( = 0.01), and total cholesterol ( = 0.02) in the entire NAFLD sample. Between groups, there were lower values of aminotransferases strictly in individuals with NASH (AST,  = 0.002; ALT,  = 0.0007) and with MetS (AST,  = 0.002; ALT,  = 0.001). The rs3781907-G was associated with lower GGT elevation values in the entire NAFLD sample ( = 0.002), in the NASH group ( = 0.004), and with MetS group ( = 0.003) and with protection for advanced fibrosis ( = 0.01). The rs11235972-A was associated with lower GGT values in the entire NAFLD sample ( = 0.006) and in the NASH group ( = 0.01) and with MetS group ( = 0.005), with fibrosis absence ( = 0.01) and protection for advanced fibrosis ( = 0.01). The TAA haplotype was protective for NASH ( = 0.002), and TGG haplotype was protective for MetS ( = 0.01). gene variants were associated with protection against NASH and MetS, in addition to lower values of liver enzymes, lipid profile, BMI and, lesser fibrosis severity in the studied population.

Download full-text PDF

Source
http://dx.doi.org/10.1089/met.2020.0104DOI Listing

Publication Analysis

Top Keywords

entire nafld
16
nafld sample
16
brazilian patients
12
nash group
12
associated lower
12
lower values
12
nonalcoholic steatohepatitis
8
metabolic syndrome
8
nonalcoholic fatty
8
fatty liver
8

Similar Publications

Background: Fat accumulation in the liver is affecting 38% of the global population. It can also occur in normal-weight individuals, termed lean non-alcoholic fatty liver disease (NAFLD). This study examines Asian and Western body mass index (BMI) criteria, as well as metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) diagnostic guidelines, in lean fatty liver cases within a healthcare setting.

View Article and Find Full Text PDF

Establishment and application of murine models of alcoholic liver disease: A narrative review.

Alcohol Clin Exp Res (Hoboken)

December 2024

Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China.

In recent years, there have been significant advances in pathological research on alcoholic liver disease (ALD), with suitable animal models making a significant contribution. However, the currently established animal ALD models still have some significant drawbacks, especially the inability to induce the entire human ALD lineage, which may be related to physiological differences between animals and humans. This review comprehensively summarized the most widely used experimental models of ALD, including voluntary drinking, Lieber-DeCarli, Meadows-Cook, Tsukamoto-French, NIAAA, and the "second hit" model.

View Article and Find Full Text PDF

Background: Nonalcoholic fatty liver disease (NAFLD) comprises multiple heterogeneous pathophysiological conditions commonly evaluated by suboptimal liver biopsies. This study aimed to elucidate the role of 13 diverse histological liver scores in assessing NAFLD disease activity using an in silico pharmacometric model-based approach. We further sought to investigate various noninvasive patient characteristics for their ability to reflect all 13 histological scores and the NAFLD activity score (NAS).

View Article and Find Full Text PDF

Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables.

Metabolism

February 2025

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Medicine, Boston VA Healthcare System, Boston, MA, USA.

Background: There are no known non-invasive tests (NITs) designed for accurately detecting metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stages F2-F3, excluding cirrhosis-the FDA-defined range for prescribing Resmetirom and other drugs in clinical trials. We aimed to validate and re-optimize known NITs, and most importantly to develop new machine learning (ML)-based NITs to accurately detect MASH F2-F3.

Methods: Clinical and metabolomic data were collected from 443 patients across three countries and two clinic types (metabolic surgery, gastroenterology/hepatology) covering the entire spectrum of biopsy-proven MASH, including cirrhosis and healthy controls.

View Article and Find Full Text PDF

Steatotic liver disease.

Lancet

November 2024

Centre for Liver Research and Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. Electronic address:

Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses what was previously termed non-alcoholic fatty liver disease (NAFLD), which is now called metabolic dysfunction-associated steatotic liver disease (MASLD). Additionally, steatotic liver disease includes alcohol-related liver disease (ALD) and MetALD, the new classification for the overlap between MASLD and ALD, and rare causes of liver steatosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!